BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:16 PM
Nov 19, 2007
 |  BC Extra  |  Clinical News

Genentech presents Avastin glioblastoma data

DNA presented data from a Phase II trial to treat glioblastoma that showed Avastin bevacizumab as monotherapy and in combination with irinotecan improved the rate of progression-free survival at six months vs. historical estimates...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >